https://trial.medpath.com/news/dr-dizman-on-future-efforts-to-elucidate-benefit-with-cbm588-in-first-line-rcc-onclive 2024-08-31T15:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dipti-itchhaporia-on-health-equity-clinical-trials-and-emerging-therapies-at-esc 2024-08-31T13:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/the-promise-of-il-21-engineered-nk-cells-in-glioblastoma-treatment-targeted-oncology 2024-08-31T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-mirdametinib-for-nf1-associated-plexiform-neurofibromas 2024-08-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/more-drug-does-not-always-lead-to-more-efficacy-dr-mark-bleackley-on-the-progress-of 2024-08-31T11:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-fighting-blindness-to-conduct-a-natural-history-study-of-usher-syndrome-type-3 2024-08-31T11:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/novel-low-dose-3-in-1-blood-pressure-pill-significantly-outperforms-standard-care-study-shows 2024-08-31T10:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-triple-pill-vs-standard-care-protocols-for-hypertension-treatment-in-nigeria 2024-08-31T09:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/abemaciclib-monotherapy-elicits-no-response-in-advanced-rcc-onclive 2024-08-31T08:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-obicetrapib-a-promising-breakthrough-for-dyslipidemia-treatment 2024-08-31T08:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-august-30-2024 2024-08-31T07:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/european-study-reveals-harmful-impact-of-delayed-myasthenia-gravis-diagnosis 2024-08-31T05:51:32+00:00 weekly 0.7 https://trial.medpath.com/news/nxp800-gains-fda-orphan-drug-status-in-arid1a-deficient-ovarian-cancers 2024-08-31T04:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-in-ireland-challenges-beliefs-about-ozempic-and-similar-new-obesity-treatments 2024-08-31T00:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment 2024-08-30T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-clinical-trial-of-nh130-and-the-prediction-of-its-pharmacokinetics-using-frontiers 2024-08-30T20:39:34+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-clinical-trial-commences-for-oral-myasthenia-gravis-treatment-healio 2024-08-30T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/cellprothera-inches-closer-to-phase-iii-trial-for-heart-attack-cell-therapy-clinical-trials-arena 2024-08-30T17:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/orgenesis-car-t-org-101-demonstrates-efficacy-and-safety-in-acute-lymphoblastic 2024-08-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/an-obesity-drug-prevents-covid-deaths-study-suggests-the-new-york-times 2024-08-30T17:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-retatrutide-improves-lipid-and-cardiovascular-risk-profile-in-phase-ii-trial 2024-08-30T16:44:42+00:00 weekly 0.7 https://trial.medpath.com/news/mother-frantic-to-save-clinical-trial-that-could-cure-her-daughter-the-treatment-is-sitting-in-a-fridge 2024-08-30T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/abyss-trial-no-difference-in-outcomes-continuing-or-stopping-beta-blockers-following-mi 2024-08-30T16:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/nih-grants-funds-to-establish-network-for-nursing-home-trials 2024-08-30T15:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/benefits-of-dark-chocolate-intake-on-retinal-vessels-functionality-nature 2024-08-30T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-have-health-benefits-beyond-weight-loss-studies-find 2024-08-30T14:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/australian-first-clinical-trial-of-personalised-immunotherapy-used-on-two-perth-cancer-patients-abc 2024-08-30T13:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/an-oral-small-molecule-pcsk9-inhibitor-disclosed-by-astrazeneca 2024-08-30T13:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-cardiologist-deepak-bhatt-highlights-critical-challenges-in-clinical-trial-interpretation 2024-08-30T11:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/community-oncologists-face-growing-decision-support-crisis-amid-cancer-care-complexity 2024-08-30T10:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/us-leads-global-cancer-vaccine-research-with-47-of-clinical-trials 2024-08-30T08:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-diversity-gap-costs-healthcare-system-11-trillion-nasem-report-reveals 2024-08-30T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-pooled-analysis-published-in-the-lancet-demonstrated-reduced-risk-of-combined-cv-death-or-worsening-heart-failure-with-semaglutide 2024-08-30T03:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-ink-unveils-edcxtra-integrated-data-capture-platform-to-streamline-clinical-trials 2024-08-30T02:27:33+00:00 weekly 0.7 https://trial.medpath.com/news/and-medium-term-outcomes-of-novel-biologics-and-lightweight-synthetic-mesh-for-pubmed 2024-08-30T00:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s 2024-08-30T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/aclarion-launches-second-clinical-utility-and-economic-clue-trial-site-with-first 2024-08-29T23:46:48+00:00 weekly 0.7 https://trial.medpath.com/news/arizona-bioscience-news-u-of-a-president-salary-journey-venture-studio-ivy-brian-center 2024-08-29T23:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/inari-medical-announces-peerless-data-to-be-presented-during-the-late-breaking-morningstar 2024-08-29T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/four-new-clinical-trials-grants-from-the-cihr-for-ri-muhc-researchers-health-e-news 2024-08-29T19:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/dr-hantel-on-eligibility-criteria-associated-with-racial-ethnic-disparities-in-clinical-trial 2024-08-29T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-ensitrelvir-for-asymptomatic-or-mild-covid-19-an-exploratory 2024-08-29T19:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/health-matters-mental-health-edition-methamphetamine-addiction-a-larc-clinical-trial 2024-08-29T18:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-attempt-to-emulate-a-clinical-trial-using-data-from-real-patients-medical-xpress 2024-08-29T18:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-tackles-clinical-trial-diversity-is-congress-next-national-health-council 2024-08-29T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-aims-to-test-tolerability-of-felodipine-in-hd-rare-disease-advisor 2024-08-29T17:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-fails-lung-and-skin-cancer-trials-limiting-further-expansion-biopharma-dive 2024-08-29T16:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials-merck-com 2024-08-29T16:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ireland-steps-up-efforts-to-boost-clinical-trial-performance-by-standardizing-ctas 2024-08-29T16:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/nih-r01-grant-awarded-to-dr-vajravelu-for-novel-clinical-trial 2024-08-29T16:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/cambridgeshire-boy-takes-part-in-brain-tumour-drug-trial-cambridge-children-s 2024-08-29T15:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-fails-phase-3-trial-in-japan-bat-set-to-see-growth-from-cannabis-investment 2024-08-29T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-assesses-the-efficacy-of-suvorexant-in-reducing-delirium-in-older-adults 2024-08-29T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/neura-launches-world-s-largest-clinical-trial-for-phantom-limb-pain-news-hub 2024-08-29T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/melodi-health-announces-10-75-million-in-series-a-funding-first-enrollment-in-pivotal-clinical-trial 2024-08-29T13:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-ceo-provides-video-update-to-shareholders-on-progress-of-world-first-thenewswire 2024-08-29T13:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-wclc-and-esmo-2024 2024-08-29T11:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-reports-positive-data-from-phase-ii-schizophrenia-treatment-trial 2024-08-29T11:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/gain-therapeutics-announces-positive-topline-results-from-the-phase-1-clinical-trial-of-gt 2024-08-29T11:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/don-t-delay-covid-19-booster-vaccination-study-reveals-doherty-website 2024-08-29T10:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/migraine-drug-ubrelvy-may-stop-headaches-before-they-start 2024-08-29T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-strategic-reprioritization-to-focus-on-broad-clinical-portfolio 2024-08-29T10:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/offering-peace-of-mind-peanut-immunotherapy-clinical-trials-at-lurie-children-s-eurekalert 2024-08-29T08:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/transcenta-holding-limited-stock-code-6628-hk-announce-2024-interim-results 2024-08-29T07:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-august-28-2024-cgtlive-r 2024-08-29T07:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/human-papillomavirus-hpv-trials-a-cross-sectional-analysis-of-clinical-trials-registries-pubmed 2024-08-29T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-for-mpox-indication 2024-08-29T04:08:02+00:00 weekly 0.7 https://trial.medpath.com/news/umass-chan-scientist-shan-lu-reports-on-effectiveness-of-dna-vaccine-to-prevent-hiv 2024-08-29T04:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/randomized-controlled-trial-assessing-vitamin-d-s-role-in-reducing-bppv-recurrence-pubmed 2024-08-29T00:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/qlife-holding-ab-interim-report-q2-april-to-june-2024 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-guard-therapeutics-phase-2b-study-pointer 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-observational-study-claiming-certain-diabetes-drugs-might-prevent-dementia 2024-08-28T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-utah-health-participates-in-groundbreaking-pain-management-research-study 2024-08-28T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/estimating-cure-proportion-in-cancer-clinical-trials-using-flexible-parametric-cure-models 2024-08-28T19:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/gatc-mci-team-on-ai-clinical-trial-funding-and-insurance-model-informa-connect 2024-08-28T19:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/participant-visits-complete-in-phase-2b-trial-of-cls-ax-for-wet-amd-healio 2024-08-28T19:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/news-dosing-underway-in-world-s-first-in-vivo-crispr-trial-for-primary-hyperoxaluria 2024-08-28T19:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/verve-therapeutics-investor-sues-over-clinical-trial-stoppage-bloomberg-law-news 2024-08-28T18:36:51+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-her-vaxx-a-b-cell-peptide-based-vaccine-in-her2-overexpressing 2024-08-28T17:45:49+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-therapies-a-new-frontier-in-mash-treatment-clinical-trials-arena 2024-08-28T17:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/optimi-health-atma-receive-no-objection-letter-from-health-canada-for-phase-2-clinical-trial 2024-08-28T16:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-secures-ps400-million-investment-to-boost-clinical-trials-gov-uk 2024-08-28T16:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/new-brain-tumor-drug-hits-market-16-years-after-duke-neurosurgeon-s-discovery-abc11 2024-08-28T15:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/promising-mpox-drug-fails-in-trials-as-virus-spreads-wired 2024-08-28T15:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial 2024-08-28T14:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/emvenio-s-clinical-research-sites-at-prime-healthcare-hospitals-now-open-in-dallas-and-atlanta 2024-08-28T14:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/notable-uh-and-cwru-clinician-researcher-and-educator-robert-salata-md-facp 2024-08-28T14:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/hyundai-bioscience-to-conduct-phase-3-clinical-trial-for-high-risk-group-of-covid-19-patients 2024-08-28T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-twice-yearly-leqvio-r-demonstrated-clinically-meaningful-statistically-significant 2024-08-28T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/game-changer-take-home-blood-cancer-drug-to-be-offered-by-nhs-england 2024-08-28T12:33:04+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-technology-driven-solutions-to-boost-minority-representation-in-cll-clinical-trials 2024-08-28T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-experts-to-host-webinar-on-scientific-storytelling-in-medical-publications 2024-08-28T07:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/crf-announces-tct-2024-late-breaking-clinical-trials-and-science 2024-08-28T07:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/wanted-t1d-participants-for-clinical-trial-to-test-semaglutide-jdrf-australia 2024-08-28T06:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-taking-place-in-houston-for-those-who-want-to-stop-smoking-lose-weight 2024-08-28T03:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-08-28T03:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/trailblazers-in-innovation-medical-college-of-wisconsin 2024-08-28T02:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/waiver-of-local-clinical-trial-requirements-by-csdso-a-well-deliberated-move-shweta-rai 2024-08-28T02:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-introduces-lower-cost-single-dose-zepbound-vials-to-expand-obesity-treatment-access 2024-08-28T00:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-1h-2024-financial-results-pipeline-progress-and 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eshunt-r-system-receives-fda-breakthrough-device-designation 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-astellas-padcev-tm-enfortumab-vedotin-in 2024-08-27T23:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/nebulized-enriched-heparin-improves-respiratory-parameters-in-patients-with-covid-19 2024-08-27T22:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/projenx-announces-formation-of-clinical-advisory-board-pr-newswire 2024-08-27T21:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/investigating-immune-tolerance-in-celiac-disease-avalon-clinical-trial 2024-08-27T20:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/next-level-breast-reconstruction-after-cancer-university-of-houston 2024-08-27T19:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/limited-impact-of-cannabidiol-on-health-related-quality-of-life-of-people-with-long-term-controlled-hiv 2024-08-27T19:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-dosing-complete-in-phase-1-trial-of-aiv007-for-amd-diabetic-macular-edema 2024-08-27T19:11:06+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-registers-clinical-trial-on-wegovy-s-long-term-effects-on-teens-quartz 2024-08-27T18:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/jw-therapeutics-relma-cell-approved-in-china-for-r-r-mantle-cell-lymphoma 2024-08-27T18:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/xlhed-clinical-trial-opens-new-site-in-los-angeles 2024-08-27T17:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/thoracic-oncology-program-research-ucsf 2024-08-27T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-on-brain-spinal-communication-in-opioid-withdrawal-lead-to-a-clinical-trial 2024-08-27T16:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-engineered-cell-therapy-for-advanced-synovial-sarcoma-national-cancer-institute 2024-08-27T16:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-nasal-vaccine-ready-for-clinical-trials-inside-precision-medicine 2024-08-27T15:18:54+00:00 weekly 0.7 https://trial.medpath.com/news/harvard-apparatus-regenerative-technology-secures-5m-to-continue-clinical-trial 2024-08-27T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-closes-phase-iii-eye-drop-trial-due-to-third-party-administrative-error-biospace 2024-08-27T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/atlantic-veterinary-college-initiates-clinical-trial-for-treatment-of-cardiac-tumours-in-dogs 2024-08-27T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-for-first-lung-cancer-vaccine-underway-where-in-va-and-md-is-it-being-tested 2024-08-27T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-initiates-phase-3-clinical-study-of-fezolinetant-for-vms-in-women-with-breast 2024-08-27T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-receives-approval-for-phase-iii-trial-of-urothelial-carcinoma-drug-in-china 2024-08-27T12:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes 2024-08-27T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/diakonos-oncology-secures-funds-for-phase-ii-trial-of-dendritic-cell-vaccine 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/gi-innovation-and-msd-partner-for-trial-of-gi-102-and-keytruda-regimen-for-cancer 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for 2024-08-27T10:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/opna-bio-doses-first-subject-in-phase-i-trial-of-treatment-for-multiple-myeloma 2024-08-27T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/omny-ire-clinical-trial-completes-enrolment-cardiac-rhythm-news 2024-08-27T09:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb097-microbiome-therapy-for-advanced-melanoma 2024-08-27T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-morningstar 2024-08-27T07:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/c-difficile-vaccine-candidate-fails-to-meet-primary-end-point-in-phase-3-trial-cidrap 2024-08-27T07:35:28+00:00 weekly 0.7 https://trial.medpath.com/news/unm-launches-clinical-trial-using-heated-chemo-for-ovarian-cancer-new-mexico-sun 2024-08-27T06:53:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-phoenix-offering-hope-for-brain-cancer-patients-azfamily 2024-08-27T06:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-and-pancreatic-cancer-europe-unite-to-enhance-clinical-trial-access-across-europe 2024-08-27T05:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-priority-review-of-nda-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-08-27T05:08:33+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-and-barda-enter-partnership-to-progress-decentralized-clinical-research-program 2024-08-27T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/par-24-274-nci-research-specialist-clinician-scientist-award-r50-clinical-trial-not-allowed 2024-08-27T04:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/intermittent-energy-restriction-for-adolescents-with-obesity-the-fast-track-to-health 2024-08-27T00:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-blood-stem-cell-transplants-for-sickle-cell-appear-safe-for-lung-health 2024-08-27T00:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with 2024-08-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-important-information-about-risk-of-covid-19-due-to-sars-cov-2-viral-variants-with-substantially-reduced-susceptibility-to-pemgarda-pemivibart 2024-08-26T23:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-approach-helps-more-people-with-rectal-cancers-avoid-surgery 2024-08-26T09:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/an-alzheimer-s-drug-may-also-slow-lewy-body-dementia 2024-08-26T09:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/mckesson-acquires-2-49-billion-controlling-stake-in-florida-cancer-specialists-to-expand-community-oncology-platform 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-announces-fda-acceptance-for-globenewswire 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-s-steqeyma-gets-ec-approval-for-inflammatory-diseases 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/si-bone-sibn-receives-fda-nod-for-its-tnt-implant-system 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xaluritamig-a-promising-new-therapeutic-for-metastatic-castration-resistant-prostate-cancer 2024-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/izotropic-plans-regulatory-approval-for-izoview-breast-ct-in-u-s-and-eu 2024-08-23T13:46:57+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-helps-patients-with-heart-failure-avoid-heart-attack-stroke 2024-08-23T09:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/no-link-found-between-migraines-parkinson-s-disease 2024-08-23T09:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-faces-nasdaq-delisting-over-equity 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-cancer-vaccine-clinical-trials-insight 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-journal-of-american-medical-association-jama-publishes-elinzanetant-phase-iii-data 2024-08-22T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-receives-u-s-fda-approval-for-updated-covid-19-vaccine-targeting-kp-2-variant-of-sars-cov-2 2024-08-22T22:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-initiates-phase-ii-study-of-soluble-guanylate-cyclase-activator-bay3283142-in-patients-with-chronic-kidney-disease 2024-08-22T22:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-alzheimer-s-drug-lecanemab-despite-mhra-approval-creating-two-tier-access-system 2024-08-22T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-leadership-changes-reshape-pharmaceutical-services-landscape-in-july-2024 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/federal-circuit-reverses-patent-invalidation-for-allergan-s-ibs-d-drug-viberzi-in-landmark-double-patenting-case 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/molecule-one-pager-kt-474-sar444656 2024-08-21T21:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/leclaza-in-combination-with-rybrevant-receives-first-u-s-fda-approval-for-a-korea-born-anticancer-drug 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-announces-fda-advisory-committee-globenewswire 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-08-20T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-orange-book-patent-challenge-initiative-shows-mixed-results-as-most-listings-remain-in-force 2024-08-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight 2024-08-20T05:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab 2024-08-20T02:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-receives-us-fda-breakthrough-therapy-designation-for-b7-h3-targeted-antibody-drug-conjugate-gsk5764227-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20T02:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild 2024-08-19T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/moma-therapeutics-initiates-phase-1-trial-for-novel-dna-repair-inhibitor-moma-313 2024-08-19T11:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout 2024-08-19T02:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/tafasitamab-regimen-shows-promise-in-improving-pfs-for-advanced-follicular-lymphoma-patients 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-announces-new-treatment-regimens-for-drug-resistant-tuberculosis 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-biontech-covid-flu-combo-vaccine-faces-setback-due-to-influenza-b-response 2024-08-18T23:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-completed-for-phase-2-clinical-trial-evaluating-vg081821ac-for-the-treatment-of-parkinson-s-disease 2024-08-18T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-for-functional-high-risk-myeloma-healthtree 2024-08-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery 2024-08-16T23:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-accepts-for-priority-review-decipheras-new-drug-application-for-vimseltinib-for-the-treatment-of-patients-with-tenosynovial-giant-cell-tumor-tgct 2024-08-16T23:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influenza-and-covid-19-in-individuals-18-64-years-of-age 2024-08-16T02:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/expanding-treatment-options-for-her2-breast-cancer-patients 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citius-oncology-launches-following-fda-approval-of-lymphir 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ptab-invalidates-multiple-regeneron-eylea-patents-as-biosimilar-competition-intensifies 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-pediatric-patients-with-severe-thermal-burns 2024-08-15T20:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-genzyme-sues-sarepta-over-elevidys-gene-therapy-patent-infringement 2024-08-15T16:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/cresilon-receives-fda-clearance-for-traumagel 2024-08-15T13:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-deliver-6-billion-in-savings-with-22-79-discounts-on-10-blockbuster-medications 2024-08-15T08:35:46+00:00 weekly 0.7 https://trial.medpath.com/news/tecovirimat-is-safe-but-did-not-improve-clade-i-mpox-resolution-in-democratic-republic-of-the-congo 2024-08-15T02:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome 2024-08-15T00:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-announces-successful-end-of-phase-2-meeting-with-fda-for-amezalpat-tpst-1120-to-treat-first-line-hepatocellular-carcinoma 2024-08-15T00:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-granted-priority-review-and-breakthrough-therapy 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-atsn-201-for-x-linked-retinoschisis 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-double-blind-placebo-controlled-phase-3 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd 2024-08-14T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-livdelzi-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-08-14T22:08:15+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-announces-second-quarter-and-first-half-2024-financial-results-and-business-updates 2024-08-14T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-pnh-treatment-new-therapies-transform-management-of-rare-blood-disorder 2024-08-14T11:24:32+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-launches-personalised-cancer-vaccine-program-across-england-with-thousands-expected-to-enroll 2024-08-14T06:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-multi-omics-drive-breakthrough-advances-in-anti-aging-drug-development 2024-08-14T05:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/first-clinical-trial-of-paradoxical-intervention-for-cancer-to-begin-soon 2024-08-14T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-her2-breast-cancer 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/candidate-malaria-vaccine-provides-lasting-protection-in-nih-sponsored-trials 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-submits-completed-ugn-102-nda-seeking-approval-as-the-first-fda-approved-treatment-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2024-08-14T01:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-advances-aml-treatment-with-positive-fda-feedback-and-plans-for-phase-3-miracle-trial 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-phase-3-data-for-izokibep-biospace 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-stock-rating-downgraded-amid-pipeline-shift 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-completed-for-the-sad-part-1-of-phase-1-clinical-trial-evaluating-da-1726-for-the-treatment-of-obesity 2024-08-13T23:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nemluvio-nemolizumab-for-the-treatment-of-adult-patients-with-prurigo-nodularis 2024-08-13T21:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-lands-eur15m-to-advance-liver-regeneration-drug-into-clinical 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-announces-layoffs-strategy-shift-after-late-stage-trial-results-for-anti-inflammatory-drug 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-platforms-transform-precision-medicine-development-through-advanced-data-analytics 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/federal-court-denies-novartis-injunction-against-entresto-generic-clearing-path-for-msn-launch 2024-08-12T22:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-4d-molecular-therapeutics-fabry-disease-gene-therapy-trial 2024-08-12T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-reports-progress-in-q2-2024-earnings-call 2024-08-12T14:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-s-amx0035-shows-promise-in-alzheimer-s-disease-biomarker-study 2024-08-12T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacosmos-group-acquires-g1-therapeutics-for-405-million-to-expand-cosela-access-for-cancer-patients 2024-08-12T09:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-enzeevu-aflibercept-abzv-a-biosimilar-to-eylea 2024-08-12T06:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/scpharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-indication-in-heart-failure 2024-08-12T01:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia 2024-08-12T01:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/viva-biotech-s-portfolio-companies-make-significant-strides-in-biopharmaceutical-innovation 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-secures-fda-approval-for-bcma-car-t-therapy-in-multiple-autoimmune-diseases 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brazil-cancer-drugs-market-clinical-trials-report-2024-brazil-emerges-as-a-leading-force-in-cancer-drug-clinical-trials 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-sglt2-inhibitors-improve-renal-function-in-non-diabetic-ckd-patients 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a 2024-08-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofis-sarclisa-wins-in-transplant-eligible-multiple-myeloma-trial 2024-08-10T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd 2024-08-09T21:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/first-patients-enrolled-in-us-pivotal-study-of-ai-based-image-analysis-module-for-lung-cancer 2024-08-09T21:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-neffy-epinephrine-nasal-spray-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis 2024-08-09T07:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd-calling-for-additional-study 2024-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-08-08T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/westgene-to-advance-clinical-trials-following-dual-ind-approvals-for-world-s-first-eb-virus-related-mrna-therapeutic-cancer-vaccine 2024-08-08T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-shares-price-target-rises-on-positive-development 2024-08-08T11:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-provides-an-update-on-its-clinical-program 2024-08-08T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/blarcamesine-shows-significant-slowing-of-alzheimer-disease-in-phase-2-3-trial 2024-08-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/policy-change-alone-wont-achieve-equity-in-clinical-trial-participation 2024-08-08T09:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-fda-accelerated-approval-for-fabhalta-iptacopan-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy-igan 2024-08-08T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap 2024-08-08T06:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keyvibe-008-trial-evaluating-an-investigational-fixed-dose-combination-of-vibostolimab-and-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer 2024-08-08T06:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-eyes-phase-iii-dravet-syndrome-trial-as-fda 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-announces-clinical-results-from-german-real-world-registry 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-bio-announces-200m-series-b-financing-to-advance-upb-101-for 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-second-quarter-2024-financial-results-and 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-announces-fda-clearance-of-ind-application-for-menin-inhibitor-ziftomenib-in-advanced-gastrointestinal-stromal-tumors-gist 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-approves-first-crispr-gene-editing-therapy-for-beta-thalassaemia-treatment 2024-08-07T23:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zurnai-nalmefene-hydrochloride-auto-injector-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2024-08-07T21:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-crexont-carbidopa-and-levodopa-extended-release-capsules-for-the-treatment-of-parkinsons-disease 2024-08-07T08:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-severe-hemolytic-disease-of-the-fetus-and-newborn-published-in-the-new-england-journal-of-medicine 2024-08-07T05:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/nice-approves-eladynos-for-postmenopausal-osteoporosis-but-nhs-diagnostic-gaps-pose-access-challenges 2024-08-07T01:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-announces-half-year-report-2024-and-provides-update 2024-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-reports-second-quarter-2024-financial-results-and-corporate-update 2024-08-06T21:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/julys-molecules-on-the-move 2024-08-06T21:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-voranigo-vorasidenib-for-the-treatment-of-grade-2-idh-mutant-glioma 2024-08-06T19:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/xdemvy-the-first-fda-approved-treatment-for-demodex-blepharitis 2024-08-06T16:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/eo-3021-shows-promise-in-treating-advanced-solid-tumors-expressing-cldn18-2 2024-08-06T16:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gerds-on-unmet-needs-in-low-risk-myelofibrosis 2024-08-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safe-and-intriguing-natures-drugs-taking-on-complex-diseases 2024-08-06T09:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-and-merck-expand-collaboration-to-develop-novel-dll3-targeting-t-cell-engager-for-small-cell-lung-cancer 2024-08-06T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-kerendia-and-nubeqa-drive-strong-pharmaceutical-growth-q2-sales-hit-eur11-1-billion 2024-08-06T03:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/george-medicines-announces-gmrx2-nda-filing-to-fda 2024-08-06T02:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-survival-benefit-in-cancer-patients-with-type-2-diabetes 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-s-abtect-phase-3-trial-reaches-key-enrollment-milestone 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shanton-pharma-completes-enrollment-for-phase-2b-trial-of-sap-001-in-refractory-gout 2024-08-05T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/turn-therapeutics-topical-atopic-dermatitis-candidate-significantly-inhibits-key-cytokines-in-expansion-study-of-flagship-formula 2024-08-05T11:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nanoparticle-immunotherapy-shows-promise-in-delaying-prostate-cancer-treatment-resistance 2024-08-05T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitors-boost-immunotherapy-response-rates-in-lung-cancer-and-lymphoma-trials 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enzene-biosciences-establishes-50-million-new-jersey-manufacturing-facility-with-continuous-biologics-platform 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-e-platform-shows-promise-in-preventing-car-t-cell-therapy-relapse 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d-printing-revolutionizes-microneedle-manufacturing-for-enhanced-transdermal-drug-delivery 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-inc-announces-fda-approval-of-expanded-access-program-for-patients-with-retinitis-pigmentosa 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-and-gene-therapy-shows-early-promise-against 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-and-sanegenebio-announce-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3016 2024-08-04T02:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c 2024-08-02T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-awards-orphan-drug-designation-to-avutometinib-plus-defactinib-for-pancreatic-cancer-treatment 2024-08-02T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-weight-loss-drug-tirzepatide-approved-in-china 2024-08-02T08:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-july-2024-roundup-breakthroughs-and-milestones 2024-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-pioneer-jim-wilson-departs-upenn-to-launch-two-new-companies 2024-08-01T13:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/ideate-lung02-phase-3-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer 2024-08-01T06:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-jemperli-dostarlimab-gxly-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-08-01T04:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/dose-dense-chemotherapy-preferred-for-node-positive-breast-cancer-patients-regardless-of-bmi 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/resmetirom-and-glp-1-agonists-show-promise-in-treating-mash 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapy-in-high-grade-serous-ovarian-cancer 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-startup-airna-raises-60m-for-rna-editing-medicines 2024-07-31T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citryll-completes-phase-i-dosing-for-novel-anti-inflammatory-drug-cit-013-targeting-neutrophil-extracellular-traps 2024-07-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fibrogen-terminates-pamrevlumab-development-after-failed-pancreatic-cancer-trials-announces-major-workforce-reduction 2024-07-31T02:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/hispanic-patients-with-alcohol-use-disorder-at-higher-risk-for-liver-diseases 2024-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-announces-positive-topline-phase-2-results-for-mrna-immunotherapy-candidate-bnt111-in-patients-with-advanced-melanoma 2024-07-30T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-s-revita-system-receives-fda-breakthrough-device-designation 2024-07-30T11:27:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-compugen-s-phase-i-trial-for-solid-tumour-treatment 2024-07-30T10:51:51+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-discontinues-duchenne-gene-therapy-development-following-phase-3-trial-failure 2024-07-30T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/psoriasis-drug-ustekinumab-shows-promise-in-preserving-insulin-production-in-young-type-1-diabetes-patients 2024-07-30T09:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/high-court-rules-on-moderna-pfizer-biontech-covid-19-vaccine-patent-dispute-setting-precedent-for-mrna-technology-rights 2024-07-30T08:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-announces-fda-acceptance-of-new-drug-application-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain 2024-07-30T02:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2024-07-30T02:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-blinatumomab-approval-in-early-stage 2024-07-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia 2024-07-29T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zunveyl-benzgalantamine-for-the-treatment-of-alzheimer-s-disease 2024-07-29T20:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/nt-0796 2024-07-29T14:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-flagship-pioneering-launch-7-billion-strategic-alliance-for-novel-therapeutics-development 2024-07-29T12:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/promis-reports-positive-phase-ia-trial-results-for-alzheimer-s-treatment 2024-07-29T08:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-receives-approval-for-expanded-xembify-immune-globulin-subcutaneous-human-klhw-label-in-u-s 2024-07-29T05:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia 2024-07-29T02:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/volunteers-needed-for-the-dog-aging-project 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lomecel-b-meets-key-objectives-in-phase-iia-alzheimer-s 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-granted-fda-priority-review-for-the 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-blood-based-cancer-test-in-medical-breakthrough 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fnih-study-validates-blood-tests-for-alzheimer-s-detection-potentially-replacing-invasive-spinal-taps 2024-07-28T11:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-erzofri-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder 2024-07-28T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/alector-presents-baseline-characteristics-for-invoke-2-phase-2-clinical-trial-of-al002-at-the-alzheimer-s-association-international-conference-r-2024-aaic-r 2024-07-28T01:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-palforzia-peanut-arachis-hypogaea-allergen-powder-dnfp-for-use-in-individuals-ages-1-through-3-years-with-a-confirmed-diagnosis-of-peanut-allergy 2024-07-26T23:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata 2024-07-26T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/xspray-pharma-shares-new-information-on-dasynoc-a-novel-cml-treatment-in-development 2024-07-26T20:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/cbm588-may-improve-clinical-outcomes-in-metastatic-rcc 2024-07-26T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-completes-u-s-recruitment-for-phase-3-glaucoma-trial-of-ncx-470 2024-07-26T10:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/third-arc-secures-165m-series-a-to-advance-novel-t-cell-engager-platform-for-cancer-and-inflammation 2024-07-26T03:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/nih-researchers-discover-potential-therapeutic-target-for-degenerative-eye-disease 2024-07-26T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/guardant-health-invests-in-obviohealth-to-accelerate-digital-oncology-clinical-trials 2024-07-26T02:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/presage-biosciences-announces-first-patient-dosing-of-pure-biologics-ror1-targeting-antibody-for-treatment-of-cancer 2024-07-26T02:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/five-key-strategies-to-revolutionize-clinical-trial-patient-recruitment-in-biopharma 2024-07-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-completes-first-patient-dosage-of-p53-y220c-activator-in-clinical-trial 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-second-covid-19-vaccine-as-moderna-receives-conditional-marketing-authorization-in-eu 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-receives-project-award-oracle-announces-new-ai-capabilities-for-trials-n-power-merck-collaborate-on-oncology-clinical-research-more 2024-07-25T09:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/mirums-livmarli-now-approved-for-pfic-in-patients-12-months-and-older 2024-07-25T01:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/evidence-meta-analysis-evaluating-minimal-residual-disease-as-an 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-announces-clinical-supply-agreement-with 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-therapeutics-provides-update-on-istaroxime-clinical-development-and-upcoming-clinical-trial-data 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-or-frontotemporal-dementia 2024-07-24T21:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-324-biib124-for-the-treatment-of-essential-tremor 2024-07-24T20:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/triastek-and-biontech-partner-to-develop-3d-printed-oral-rna-therapeutics-in-1-2-billion-deal 2024-07-24T10:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-announces-positive-topline-results-from-phase-3-study-of-hemophilia-a-gene-therapy-candidate-giroctocogene-fitelparvovec 2024-07-24T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock 2024-07-24T03:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-biomarin-s-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/consynance-therapeutics-receives-fda-rare-pediatric-disease-designation-for-csti-500-in-prader-willi-syndrome 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/glecirasib-a-promising-novel-kras-g12c-inhibitor-in-clinical 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update-biospace 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nci-launches-cervical-cancer-last-mile-initiative-to-expand-screening-access 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2206-a-proposed-biosimilar-to-stelara-r-in-the-us-and-eu 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-gene-therapy-approach-shows-promise-for-duchenne-muscular-dystrophy 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-femlyv-norethindrone-acetate-and-ethinyl-estradiol-orally-disintegrating-birth-control-pill 2024-07-23T23:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/merz-aesthetics-announces-fda-approval-of-xeomin-incobotulinumtoxina-as-the-first-and-only-u-s-neurotoxin-for-the-simultaneous-treatment-of-upper-facial-lines 2024-07-23T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/iopofosine-i-131-achieves-major-response-rate-in-relapsed-refractory-waldenstrom-macroglobulinemia 2024-07-23T16:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/millions-more-brits-could-get-weight-loss-jabs-on-nhs-to-prevent-heart-attack-and-stroke-are-you-e 2024-07-23T16:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmission-of-bla-for-remestemcel-l-in-pediatric-steroid-refractory-acute-graft-vs-host-disease 2024-07-23T15:23:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-sbla-for-susvimo-in-diabetic-eye-diseases-following-promising-phase-3-results 2024-07-23T14:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/an-isolated-viral-load-test-may-generate-false-positive-results-for-people-using-long-acting-prep 2024-07-23T04:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/long-acting-injectable-cabotegravir-for-hiv-prevention-is-safe-in-pregnancy 2024-07-23T04:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-topline-results-from-phase-2b-3-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants 2024-07-23T04:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/ema-issues-precautionary-measures-for-valproate-use-in-male-patients-due-to-potential-neurodevelopmental-risks 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-initiates-phase-2-trial-of-fast-acting-psychedelic-re104-for-postpartum-depression 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-epysqli-eculizumab-aagh-a-biosimilar-to-soliris 2024-07-22T20:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/synaptixbio-secures-second-fda-orphan-drug-designation-for-tubb4a-leukodystrophy-variant 2024-07-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/60-degrees-pharmaceuticals-initiates-clinical-trials-for-babesiosis-treatment 2024-07-22T08:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-predictive-analytics-set-to-transform-cancer-patient-care-and-treatment-outcomes 2024-07-22T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw191-a-novel-folate-receptor-targeted-topoisomerase-i-inhibitor-antibody-drug-conjugate 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-new-heart-failure-implant-its-breakthrough-device 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/once-daily-gildeuretinol-acetate-shows-promise-in-halting-early-stage-stargardt-disease-progression 2024-07-21T18:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-receives-fda-positive-feedback-for-expanding-gene-therapy-trial-to-include-ftd-c9orf72-patients 2024-07-19T22:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zituvimet-xr-sitagliptin-and-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2024-07-19T19:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-data-explosion-industry-grapples-with-283-increase-in-phase-iii-data-collection 2024-07-19T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rezatapopt-takes-aim-at-previously-untargetable-p53 2024-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-commission-president-unveils-ambitious-2025-biotech-act-to-boost-european-life-sciences 2024-07-18T22:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults 2024-07-18T21:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advises-against-accelerated-approval-for-botensilimab-balstilimab-in-mss-colorectal-cancer-despite-phase-3-advancement 2024-07-18T15:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-non-proliferative-diabetic-retinopathy 2024-07-18T13:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/asrs-2024-examining-real-world-use-of-faricimab-through-the-faretina 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-achieves-significant-pipeline-progress-in-first-half-of-2024 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-clinical-success-rates-drop-to-6-7-amid-evolving-r-d-landscape 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-develop-breakthrough-anti-ageing-drug-that-extends-lifespan-by-25 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trofinetide-shows-promise-as-a-treatment-for-rett-syndrome 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-advances-overcoming-challenges-in-solid-tumors-and-enhancing-safety-through-innovative-engineering 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-r-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-07-17T23:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/brentuximab-vedotin-triplet-shows-significant-survival-benefits-in-relapsed-refractory-dlbcl 2024-07-17T19:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-arizona-commercial-use-of-new-cancer-therapy-shows-promising-results 2024-07-17T15:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-post-transcriptional-rna-modification-with-a-first-to-clinic-mettl3-inhibitor-stc15 2024-07-17T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/orexo-receives-a-complete-response-letter-regarding-the-nda-for-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose 2024-07-17T00:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-investigational-new-drug-application-for-muscular-dystrophy-treatment-from-university-of-minnesota-startup-myogenica 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-novel-b7-h3-targeting-adc-in-sclc 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-receives-december-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission 2024-07-16T21:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/tenosynovial-giant-cell-tumors-treatment-market-to-see-significant-growth-by-2034 2024-07-16T05:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trials-landscape-reveals-promising-advances-in-non-small-cell-lung-cancer-treatment 2024-07-16T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/more-men-with-advanced-prostate-cancer-could-benefit-from-precision-drug-olaparib 2024-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-completes-end-of-phase-2-meeting-for-annamycin-plus-cytarabine-in-aml 2024-07-15T15:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-07-15T04:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-publishes-positive-phase-2b-results-for-topical-sildenafil-cream-in-female-sexual-arousal-disorder 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-adagrasib-with-cetuximab-for-kras-g12c-mutated-advanced-colorectal-cancer 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maralixibat-shows-promise-in-treating-progressive-familial-intrahepatic-cholestasis 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-for-stiff-person-syndrome-granted-fast-track-designation-from-fda-fox-news 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-alzheimer-s-drug-obtains-fda-approval-here-s-why-the-stock-isn-t-taking-off 2024-07-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/msd-completes-3-billion-acquisition-of-eyebio-gaining-novel-retinal-disease-candidate-restoret 2024-07-12T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-approaches-reshape-rare-disease-drug-development-experts-outline-path-to-success 2024-07-12T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/w-t7-shows-encouraging-response-rate-manageable 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-immunotherapy-combination-shows-promise-against-common-colorectal-cancer-in-phase-1-trial 2024-07-11T13:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/is-eli-lilly-lly-a-buy-on-tirzepatide-success-in-sleep-apnea 2024-07-11T12:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-btk-degraders-show-promise-in-treating-resistant-b-cell-malignancies 2024-07-11T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/fresh-take-on-how-to-conduct-rare-disease-clinical-trials 2024-07-11T09:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-fda-approval-for-phase-2-obesity-trial-of-bio101-to-address-muscle-loss-in-glp-1-therapy 2024-07-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genai-poised-to-transform-pharmaceutical-medical-writing-despite-implementation-challenges 2024-07-11T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-cancer-vaccines-clinical-trials-market-opportunity 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-inc-announces-change-to-auditor-financial-post 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amivantamab-plus-lazertinib-improves-pfs-over 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delhi-high-court-bans-zydus-pertuzumab-biosimilar-sigrima-in-patent-infringement-case 2024-07-10T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-and-challenges-in-renal-cell-carcinoma-treatment 2024-07-10T16:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/hybryte-shows-promising-results-in-early-stage-cutaneous-t-cell-lymphoma-treatment 2024-07-10T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-acquires-phase-3-ready-glp-1-receptor-antagonist-avexitide-for-hyperinsulinemic-hypoglycemia 2024-07-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-orphan-designations-for-rare-disease-treatments-in-pulmonary-fibrosis-and-b-cell-lymphoma 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-safety-findings-among-persons-aged-60-years 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age 2024-07-09T22:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-generic-methimazole-solution-for-feline-hyperthyroidism-treatment 2024-07-09T16:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-advances-in-clinical-trials-and-expands-into-obesity-treatment 2024-07-09T09:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-initiates-phase-3-trial-of-int230-6-for-metastatic-sarcoma 2024-07-09T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/nda-resubmission-planned-for-rivoceranib-camrelizumab-in-onclive 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-s-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free-survival-following-statistically-significant-slowing-of-disease-progression 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/flot-perioperative-chemotherapy-extends-survival-over-cross-protocol-in-esophageal-cancer 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comparing-long-term-data-for-io-io-and-io-tki-in-favorable-risk-metastatic-renal-cell-carcinoma 2024-07-08T21:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/global-breast-cancer-therapeutics-market-expected-to-reach-78-61-billion-by-2033 2024-07-08T21:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-225ac-fl-020-for-metastatic-castration-resistant-prostate-cancer 2024-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/china-dominates-ai-driven-drug-discovery-patent-landscape-reshaping-pharmaceutical-r-d 2024-07-06T20:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/cnipa-upholds-vortioxetine-crystal-form-patent-in-landmark-decision-for-pharmaceutical-ip-in-china 2024-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-genentechs-vabysmo-prefilled-syringe-pfs-for-three-leading-causes-of-vision-loss 2024-07-04T20:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-dostarlimab-expands-development-portfolio-to-target-multiple-advanced-cancers 2024-07-04T09:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/uk-survey-reveals-8-year-treatment-delay-and-severe-impact-of-chronic-hand-eczema-on-daily-life 2024-07-04T08:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-drugs-ozempic-and-wegovy-linked-to-increased-risk-of-blinding-eye-condition-in-new-study 2024-07-03T15:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-breakthrough-twice-yearly-injection-shows-100-efficacy-in-preventing-infection 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/annovis-stock-swells-after-phase-iii-parkinson-s-subgroup 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kisunla-donanemab-azbt-for-the-treatment-of-early-symptomatic-alzheimer-s-disease 2024-07-02T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-endometrial-cancer-therapies-expanding-treatment-options 2024-07-02T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-new-draft-guidance-on-diversity-action-plans-for-clinical-studies 2024-07-02T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-tezacaftor-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-07-02T05:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-in-oncology-april-june-2024-blog-aacr 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dementia-global-clinical-trials-review-2024-comparative-scenario-of-completed-and-uncompleted-terminated-suspended-withdrawn-trials 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-second-alzheimers-drug-that-can-slow-onset-of-disease-alzheimer-s-the-guardian 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-the-next-generation-of-covid-19-vaccines-abc-news 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-generates-os-benefit-in-r-r-myeloma-after-1-prior-therapy 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ahzantive-aflibercept-mrbb-a-biosimilar-to-eylea 2024-07-01T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/eirion-therapeutics-launches-first-in-human-clinical-trial-for-et-02-a-novel-treatment-for-androgenic-alopecia 2024-07-01T22:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nypozi-filgrastim-txid-a-biosimilar-to-neupogen 2024-07-01T21:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ianalumab-advances-in-phase-3-trial-for-lupus-nephritis-as-cdsco-approves-protocol-amendment 2024-07-01T18:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-07-01T06:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pyzchiva-ustekinumab-ttwe-a-biosimilar-to-stelara 2024-07-01T05:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-data-analytics-could-reduce-clinical-trial-failure-rates-by-20-quanthealth-ceo-reports 2024-07-01T01:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-nivolumab-plus-ipilimumab-reduces 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-and-imfinzi-combination-recommended-for-eu-approval-in-endometrial-cancer-treatment 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biologics-for-chronic-rhinosinusitis-with-nasal-polyps-pubmed 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/improving-clinical-trial-informed-consent-new-strategies-to-enhance-patient-understanding-and-trial-success 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kalivir-immunotherapeutics-announces-fda-clearance-of-investigational-new-drug-ind-for-oncolytic-immunotherapy-vet3-tgi-for-solid-tumors 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bionic-leg-makes-walking-quicker-and-easier-for-amputees-trial-shows-medical-research-the-guardian 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ivabradine-s-impact-on-heart-failure-with-reduced-ejection-fraction-a-systematic-review-and-meta-analysis 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kashiv-biosciences-enters-into-exclusive-licensing-agreement-with 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-zealand-patient-becomes-first-globally-to-receive-gene-therapy-for-facioscapulohumeral-muscular-dystrophy 2024-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tepylute-thiotepa-ready-to-dilute-injectable-formulation-to-treat-breast-cancer-and-ovarian-cancer 2024-06-28T22:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/infection-risk-with-btk-inhibitors-low-new-cll-study-finds 2024-06-28T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-multiple-barriers-limiting-biologic-access-for-psoriasis-patients 2024-06-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-status-to-spinogenix-s-spg601-for-fragile-x-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/drug-farm-receives-fda-ind-clearance-for-first-in-class-alpk1-inhibitor-df-003-in-rosah-syndrome 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anokion-reveals-promising-phase-1b-2-data-on-kan-101-for-celiac-disease 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-non-renewal-of-authorisation-of-duchenne 2024-06-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/epkinly-epcoritamab-bysp-approved-by-u-s-fda-for-patients-with-relapsed-or-refractory-r-r-follicular-lymphoma-fl 2024-06-27T04:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/uk-and-denmark-approve-csl-s-hemgenix-gene-therapy-for-haemophilia-b-with-novel-reimbursement-models 2024-06-27T02:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-advances-re104-psychedelic-treatment-for-postpartum-depression-with-103m-funding 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/slated-capricor-fda-meeting-to-focus-on-dmd-therapy-deramiocel 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exosome-based-cancer-therapy-advances-from-cell-free-treatment-to-targeted-drug-delivery 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-clinical-trial-underway-for-qtx3046-in-krasg12d-mutated-advanced-solid-tumors 2024-06-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/huadong-medicine-reports-positive-phase-i-results-for-oral-glp-1-receptor-agonist-hdm1002 2024-06-26T13:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-makes-significant-progress-in-mental-health-treatment-development 2024-06-26T12:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/encell-s-mesenchymal-stem-cell-therapy-shows-promise-in-first-in-human-trial-for-charcot-marie-tooth-disease 2024-06-26T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer 2024-06-26T04:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/star-therapeutics-presents-clinical-data-for-vga039-a-subcutaneous 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-announces-us-fda-approval-of-ohtuvayretm-ensifentrine 2024-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/industry-survey-reveals-healthcare-mistrust-as-major-barrier-to-clinical-trial-diversity 2024-06-25T22:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-u-s-regulatory-update-on-abbv-951-foscarbidopa-foslevodopa 2024-06-25T21:06:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-brexpiprazole-sertraline-combination-for-ptsd-review-marking-first-potential-new-treatment-in-over-20-years 2024-06-25T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-advances-parkinson-s-disease-treatment-with-phase-2-trial-of-ab-1005-gene-therapy 2024-06-25T11:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/generative-ai-poised-to-transform-clinical-trial-efficiency-with-40-faster-regulatory-submissions 2024-06-25T03:29:52+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-announces-olezarsen-new-drug-application-accepted-for-priority-review-and-enrollment-in-phase-3-shtg-program-completed 2024-06-25T01:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/riliprubart-shows-promise-as-first-in-class-treatment-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/n-power-medicine-secures-series-b-funding-to-enhance-oncology-clinical-trials-access 2024-06-24T16:54:32+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-helped-women-lose-more-weight-than-men-with-the-same-heart-condition-study-says 2024-06-24T14:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/sen-jam-pharmaceutical-completes-enrollment-for-phase-2-upper-respiratory-infection-covid-therapeutic 2024-06-24T13:56:03+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-reduces-kidney-disease-risk-by-24-in-landmark-flow-trial-for-type-2-diabetes-patients 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-gives-guidance-on-seven-clinical-readouts-within-18-months 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-announces-ema-has-initiated-review-of-the-elevidys 2024-06-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-obesity-drugs-target-muscle-preservation-and-enhanced-efficacy-beyond-glp-1-mechanisms 2024-06-23T17:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/inhale-3-trial-shows-inhaled-insulin-improves-glycemic-control-in-type-1-diabetes-patients 2024-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-receives-40th-fda-approval-for-advanced-endometrial-cancer-treatment 2024-06-21T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-panel-unanimously-recommends-approval-of-lilly-s-alzheimer-s-drug-donanemab 2024-06-21T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-advances-dual-regulatory-milestones-with-tafasitamab-bla-acceptance-and-bcl2-inhibitor-icp-248-clinical-trial-approval-in-china 2024-06-21T09:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-s-vx-880-stem-cell-therapy-achieves-insulin-independence-in-type-1-diabetes-patients 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-intends-to-seek-accelerated-approval-for-mpsiii 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-surges-on-expanded-approval-of-muscular-dystrophy-drug 2024-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rapafusyn-pharmaceuticals-raises-28-million-series-a-to-advance-non-degrading-molecular-glue-platform 2024-06-20T18:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/cocrystal-pharma-s-cc-42344-shows-activity-against-h5n1-avian-influenza-in-preclinical-studies 2024-06-20T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ionctura-secures-eur80-million-series-b-to-advance-pi3kd-cancer-therapy-through-phase-ii-trials 2024-06-20T02:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/paxlovid-reduces-risk-of-long-covid-and-post-acute-hospitalization-or-death-in-high-risk-patients 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/open-surgery-outperforms-minimally-invasive-techniques-in-cervical-cancer-treatment-study-finds 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-wins-full-approval-and-label-expansion-for-dmd-gene-therapy-biospace 2024-06-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-maintains-clinical-benefit-in-myelofibrosis-patients-despite-treatment-related-anemia 2024-06-19T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-explores-brentuximab-vedotin-for-systemic-sclerosis-treatment-in-development-pipeline 2024-06-19T09:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-blood-test-shows-promise-for-early-parkinson-s-detection-with-100-accuracy 2024-06-19T02:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-reveals-new-phase-1-trial-data-for-kt-333-patsnap 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-report-from-the-children-s-oncology-group-new-agents 2024-06-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-extends-review-timeline-for-regenxbio-s-hunter-syndrome-gene-therapy-rgx-121 2024-06-18T07:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/cll-patients-prioritize-pfs-benefits-in-treatment-choices-survey-reveals 2024-06-18T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nav1-8-inhibitors-lead-wave-of-non-opioid-pain-treatments-as-industry-tackles-opioid-crisis 2024-06-18T04:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-ventana-dp-200-digital-pathology-platform-for-clinical-diagnosis 2024-06-18T01:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-submits-new-drug-application-to-fda-for-sebetralstat-as-first-oral-on-demand-treatment-for-hereditary-angioedema 2024-06-18T00:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-pharmaceuticals-presents-real-world-data-on-daybuetm-trofinetide-for-rett-syndrome 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-in-calgary 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-skyrizi-r-risankizumab-rzaa-for-ulcerative-colitis 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-bla-to-fda-for-lung-cancer-drug 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/three-rsv-vaccines-now-available-for-older-adults-as-fda-approves-moderna-s-mresvia 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-2024-a-preview-of-trials-planned-to-initiate 2024-06-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cerevel-therapeutics-advances-emraclidine-development-for-alzheimer-s-related-dementia-and-psychosis 2024-06-17T21:52:12+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-combination-therapies-show-promise-in-high-risk-cll-sll-treatment 2024-06-17T20:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-merck-s-capvaxive-first-21-serotype-pneumococcal-vaccine-designed-specifically-for-adults 2024-06-17T17:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-lynozyfic-receives-fda-approval-for-multiple-myeloma-with-70-response-rate 2024-06-17T08:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-advances-development-program-for-hepatocellular-carcinoma-treatment 2024-06-17T07:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/pharmamar-s-trabectedin-expands-development-portfolio-with-multiple-cancer-indications 2024-06-17T07:42:59+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-bevacizumab-under-evaluation-for-endometrial-cancer-treatment 2024-06-17T07:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/argenx-to-unveil-vision-2030-and-share-updates-on-clinical-pipeline-at-r-d-day 2024-06-17T05:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promising-results-in-lupus-and-autoimmune-diseases-at-eular-conference 2024-06-17T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mendus-reports-promising-long-term-survival-data-for-vididencel-in-acute-myeloid-leukemia 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kite-s-yescarta-shows-superior-manufacturing-success-and-t-cell-performance-in-second-line-treatment-of-large-b-cell-lymphoma 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avicursen-by-percheron-therapeutics-for-duchenne-muscular-dystrophy 2024-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/calquence-plus-chemoimmunotherapy-shows-27-reduction-in-disease-progression-risk-for-untreated-mantle-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-s-novel-five-drug-combination-shows-promise-for-relapsed-aggressive-b-cell-lymphoma 2024-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-100-response-rate-in-high-risk-newly-diagnosed-multiple-myeloma-patients 2024-06-15T10:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-columvi-demonstrates-41-reduction-in-death-risk-in-phase-iii-dlbcl-trial 2024-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-plus-toripalimab-shows-early-efficacy-in-her2-positive-mibc 2024-06-14T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/liso-cel-car-t-therapy-shows-promising-results-across-multiple-lymphoma-subtypes 2024-06-14T18:03:33+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-presents-positive-clinical-data-across-portfolio 2024-06-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-blinatumomab-for-cd19-b-all-in-the 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blood-stage-malaria-vaccine-candidate-rh5-1-matrix-m-trial-in-tanzania 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-inks-deal-for-cancer-drug-trial 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/deadline-approaching-for-transitioning-clinical-trials-from-ctd-to-ctr 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-camrelizumab-an-anti-pd-1-antibody-plus-chemotherapy-or 2024-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-demonstrates-long-term-durability-in-nmibc 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-phase-iii-dmd-gene-therapy-study-misses-goal-pfizer-nyse-pfe-capricor-therapeutics-nasdaq-capr-benzinga 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-fda-panel-rejected-mdma-therapy-and-whats-next-for-psychedelic-medicine 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-advances-phase-iii-trial-for-keytruda-biosimilar-fyb206-in-non-small-cell-lung-cancer 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-axess-restorative-conduit-to-be-studied-in-fda-ide-pivotal-trial 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharmas-promising-trial-results-and-fda-progress-tipranks-com 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-holds-steady-promising-ugn-102-results-balanced-with-market-caution-markets-insider 2024-06-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oac-therapy-for-myotonic-dystrophy-type-1 2024-06-12T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/swimming-microrobots-deliver-cancer-fighting-drugs-to-metastatic-lung-tumors-in-mice 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-confirms-efficacy-and-safety-of-antibody-drug-conjugates-in-advanced-urothelial-carcinoma-treatment 2024-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-2-results-for-setrusumab-in-osteogenesis-imperfecta-treatment 2024-06-11T21:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments 2024-06-11T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-concludes-subject-enrolment-in-dry-eye-disease-trial 2024-06-11T12:58:37+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday 2024-06-11T12:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-wins-fda-approval-for-rsv-vaccine 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-rsv-vaccine-arexvy-gets-fda-nod-for-adults-50-59-years 2024-06-11T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-hormonal-gel-shows-promise-for-male-birth-control 2024-06-11T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/three-promising-drugs-for-treating-alzheimer-s-disease-bring-fresh-hope 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moonlake-immunotherapeutics-initiates-phase-3-vela-program-for-sonelokimab-in-hidradenitis-suppurativa-treatment 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-impact-of-cholesterol-changes-on-cardiovascular-disease-risk 2024-06-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upadacitinib-outperforms-dupilumab-in-landmark-level-up-trial-for-moderate-to-severe-atopic-dermatitis 2024-06-10T21:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-combination-flu-covid-vaccine-shows-superior-immune-response-in-phase-3-trial 2024-06-10T16:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-s-slow-adoption-challenges-and-progress-in-alzheimer-s-treatment 2024-06-10T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-receives-irb-approval-for-phase-iia-pancreatic-cancer-trial-of-namodenoson 2024-06-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-radiographic-evaluation-of-mineral-trioxide-aggregate-and-human-amniotic-membrane-in-primary-molar-teeth 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-iqirvo-receives-u-s-fda-accelerated-approval-for-primary-biliary-cholangitis-treatment 2024-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-eisai-s-filing-of-leqembi-r-for-alzheimer-s-disease-treatment 2024-06-09T23:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/concierge-medicine-market-set-to-reach-10-9-billion-by-2032-amid-growing-healthcare-disparities 2024-06-07T02:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/this-pharma-stock-dropped-60-premarket-as-fda-halted-diabetes-drug-trials-biomea-fusion-nasdaq-bmea-benzinga 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-shares-rise-after-fda-s-telomerase-inhibitor 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/petros-pharmaceuticals-completes-ai-integrated-study-for 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-abbv-ovarian-cancer-therapy-meets-study-goal 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rytelotm-imetelstat-for-lower-risk-mds-with-transfusion-dependent-anemia 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dual-agonist-drug-survodutide-shows-promise-in-phase-2-trial-for-fatty-liver-disease-treatment 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-geron-s-treatment-for-lower-risk-mds-blood-cancer-by-investing-com 2024-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abu-dhabi-health-department-and-novartis-partner-to-advance-genomics-research-and-radioligand-therapy 2024-06-06T22:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rescinds-marketing-ban-on-juul-vaping-products-returns-applications-to-review-status 2024-06-06T17:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-oncology-therapeutics-announces-first-patient-dosed-with-bbo-8520-in-the-onkoras-101-trial-for-krasg12c-nsclc 2024-06-06T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-year-to-date-achievements-and-highlights 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilcare-and-shionogi-form-eur400-million-partnership-to-develop-novel-hearing-loss-treatments 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-to-present-alfapump-r-safety-and-quality-of-life-data-at-easl-congress-2024 2024-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-panel-unanimously-recommends-jn-1-targeted-covid-19-vaccines-for-fall-2024 2024-06-05T21:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/bilateral-gene-therapy-restores-hearing-in-both-ears-for-children-with-inherited-deafness 2024-06-05T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/inhibikase-therapeutics-completes-enrollment-in-phase-2-trial-for-parkinson-s-disease-treatment 2024-06-05T08:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-expand-pain-portfolio-with-siteone-acquisition 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/streamlining-clinical-trials-in-finland-s-unique-environment 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-atirmociclib-in-combination-with-rly-2608 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-16-week-data-from-its-global-phase-2b-3-trial-of-izokibep-in-psoriatic-arthritis-to-be-shared-during-late-breaking-oral-presentation-at-eular-2024-biospace 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-elafibranor-demonstrates-sustained-efficacy-in-primary-biliary-cholangitis-phase-iii-trial 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco24-j-j-innovative-medicine-touts-positive-multiple-myeloma-drug-data 2024-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-weight-loss-drugs-like-ozempic-show-promising-cancer-prevention-benefits 2024-06-04T17:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-s-tak-861-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2024-06-04T13:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-clinical-trials-begin-for-twice-yearly-hiv-prevention-injection 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/carsgen-s-satri-cel-shows-promise-in-phase-1-trial-for-gastrointestinal-cancers 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ad109-advances-to-phase-iii-trials-as-first-oral-therapy-for-obstructive-sleep-apnea 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-announces-positive-3-year-efficacy 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glycomimetics-announces-comprehensive-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsed-refractory-r-r-acute-myeloid-leukemia-aml 2024-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-highlights-phase-3-sarclisa-data-in-multiple-myeloma-treatment 2024-06-03T20:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-data-shows-enhertu-reduces-breast-cancer-progression-risk-by-38-as-access-remains-denied-in-england 2024-06-03T16:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-reports-promising-results-for-atumelnant-in-treating-cah-and-acth-dependent-cushings-syndrome 2024-06-03T16:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-antibodies-show-promise-in-multiple-myeloma-treatment-across-different-patient-populations 2024-06-03T15:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/structure-s-obesity-pill-shows-promising-weight-loss-results-in-study 2024-06-03T12:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-data-shows-mirikizumab-s-efficacy-in-crohn-s-disease-treatment 2024-06-03T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-launches-qiastat-dx-gastrointestinal-panel-2-in-the-u-s-for-improved-gi-infection-diagnosis 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-advances-personalized-cancer-vaccine-tg4050-to-phase-ii-trial-in-head-and-neck-cancer 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mid-stage-trial-failure-for-sanofi-and-denali-s-als-drug 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-superior-kidney-function-preservation-in-phase-1b-transplant-trial 2024-06-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-demonstrates-84-reduction-in-disease-progression-risk-for-egfr-mutated-stage-3-nsclc 2024-06-02T12:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/2024-san-antonio-breast-cancer-symposium 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-reports-positive-clinical-data-from-cb-010-antler-phase-1-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-s-bat8006-shows-promising-37-response-rate-in-platinum-resistant-ovarian-cancer-phase-i-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/newron-myung-collaborate-for-evenamide-development-in-south-korea 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-camrelizumab-plus-rivoceranib-maintains-survival-onclive 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-shows-promise-in-platinum-resistant-ovarian-cancer-trial 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chime-mabgeek-achieve-phase-iii-milestone-with-mg-k10 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-launches-in-austria-and-germany-as-first-anti-amyloid-alzheimer-s-therapy-in-eu 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-launches-first-ustekinumab-biosimilar-autoinjector-in-europe-with-pyzchiva 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-gene-therapy-shows-potential-as-functional-cure-for-hereditary-angioedema-in-long-term-study 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-reports-77-complete-response-rate-for-padeliporfin-vtp-in-low-grade-upper-tract-urothelial-cancer 2024-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultra-sensitive-blood-test-predicts-breast-cancer-recurrence-up-to-41-months-before-clinical-symptoms 2024-06-01T23:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-amivantamab-demonstrates-superior-outcomes-over-iv-administration-in-egfr-mutated-nsclc 2024-06-01T18:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/amivantamab-plus-lazertinib-improves-pfs-irrespective-of 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-s-gohibic-vilobelimab-selected-for-first-barda-sponsored-clinical-trial 2024-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/asco-2024-highlights-breakthroughs-in-cancer-treatment 2024-05-31T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-05-31T02:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-phase-iii-data-first-to-show-superior-efficacy-with-a-favorable-safety-and-tolerability-profile-vs-standard-of-care-tkis-in-adults-with-newly-diagnosed-cml-novartis 2024-05-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strand-therapeutics-doses-first-patient-with-programmable-mrna-cancer-therapy-stx-001-in-phase-1-trial 2024-05-30T11:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-bemdaneprocel-for-parkinsons-disease 2024-05-30T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-trends-in-anti-obesity-drug-development-for-2024 2024-05-30T06:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-acknowledges-astellas-resubmission-of-biologics-license-application-for-zolbetuximab-and-sets-new-action-date 2024-05-30T05:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-101-shows-promise-as-first-antidepressant-to-reduce-suicidality-in-bipolar-depression 2024-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-advances-in-clinical-trial-for-genetic-ftd-treatment 2024-05-29T09:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-partners-with-city-of-hope-cancer-center-for-iopofosine-clinical-development 2024-05-29T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-cardamyst 2024-05-29T02:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-29T02:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-lonigutamab-phase-1-2-proof-of-concept-data-to-be-shared-during-late-breaking-oral-presentation-at-endo-2024-marketscreener 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/extended-daratumumab-krd-therapy-achieves-85-three-year-pfs-in-newly-diagnosed-multiple-myeloma-without-transplant 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-landgren-on-the-utility-of-mrd-as-an-end-point-in 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-develops-first-in-class-broad-spectrum-antiviral-agent-nv-387 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-medicine-and-pmv-pharma-partner-to-develop-companion-diagnostic-for-rezatapopt 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdc-clinical-guidelines-on-the-use-of-doxycycline 2024-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spineart-receives-fda-510-k-clearance-for-scarlet-ac-ti-anterior-cervical-cage-with-advanced-ti-life-technology 2024-05-28T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-krazati-plus-cetuximab-for-kras-g12c-mutated-colorectal-cancer 2024-05-28T14:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-expands-portfolio-with-1-25b-acquisition-of-skin-disease-medicine 2024-05-28T10:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/resminostat-s-approval-by-the-ema-and-the-fda-mhra-and-more-how 2024-05-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-pipeline-analysis-2024-insights-into-therapeutics-development 2024-05-27T18:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/remegen-s-telitacicept-receives-priority-review-for-myasthenia-gravis-treatment-following-successful-phase-iii-trial 2024-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pneumagen-s-neumifil-shows-promising-results-in-phase-2-influenza-prevention-trial 2024-05-24T16:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/ema-validates-marketing-applications-for-hlx14-denosumab-biosimilar-in-osteoporosis-treatment 2024-05-24T10:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-drug-discovery-accelerates-with-new-academic-alliance-targeting-protein-kinases 2024-05-23T14:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-vcn-01-for-metastatic-pancreatic-cancer-treatment 2024-05-23T14:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/eyp-1901-shows-promise-in-reducing-treatment-burden-for-wet-amd-patients-in-phase-2-davio-2-trial 2024-05-23T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-to-present-latest-hepatitis-delta-and-b-data-at-easl-congress-2024 2024-05-22T12:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-expands-into-immunology-with-acquisition-of-hi-bio 2024-05-22T11:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/home-immix-biopharma-inc 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-ai-predict-the-development-of-autoimmune-diseases 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-fda-meeting-outcome-for-alfapump-pma-application 2024-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-efficacy-and-safety-of-sglt2-inhibitors-in-type-2-diabetes-management 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-path-for-cingulate-s-ctx-1301-adhd-treatment-nda-submission 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-to-present-latest-clinical-data-of-hlx22-at-2024-esmo-gastrointestinal-cancers-congress 2024-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atara-biotherapeutics-submits-tabelecleucel-tab-cel-r-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-s-fda 2024-05-20T23:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/spinogenix-receives-fda-orphan-drug-designation-for-spg601-to-treat-fragile-x-syndrome 2024-05-20T13:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-vaccine-breakthrough-new-candidate-successfully-generates-broadly-neutralizing-antibodies 2024-05-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-gets-fda-approval-for-second-brain-implant-patient-wsj 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anokion-announces-promising-clinical-data-for-kan-101-in-celiac-disease-treatment 2024-05-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-non-hormonal-therapy-shows-promise-in-reducing-hot-flashes-in-phase-iii-trials 2024-05-17T11:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/progress-in-sclc-from-deadly-to-cure 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maternal-vaccine-trials-face-critical-challenges-only-6-of-late-stage-studies-include-pregnant-women 2024-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-once-weekly-insulin-efsitora-demonstrates-non-inferior-efficacy-in-phase-3-trials-for-type-2-diabetes 2024-05-16T17:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/south-rampart-pharma-s-srp-001-shows-promise-as-non-opioid-pain-treatment-in-phase-1-trial 2024-05-16T10:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/investors-launch-400m-hercules-startup-to-develop-novel-glp-1-therapies-for-obesity-and-diabetes 2024-05-16T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-amgen-s-treatment-for-most-deadly-form-of-lung-cancer 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lsu-health-new-orleans-develops-novel-non-addictive-painkiller-with-fda-fast-track-designation 2024-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optilume-bph-catheter-system-preserves-sexual-function-while-treating-luts 2024-05-15T19:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-accelerates-drug-reimbursement-process-with-new-pilot-program 2024-05-15T11:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-immunotherapy-approach-keeps-brain-cancer-at-bay-for-australian-doctor-who-helped-develop-it 2024-05-15T06:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/study-of-tecovirimat-for-human-mpox-virus-stomp 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blackstone-launches-uniquity-bio-with-300m-to-advance-anti-tslp-therapy-for-asthma-and-copd 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-advances-ons-5010-toward-potential-first-approved-ophthalmic-bevacizumab-for-retinal-diseases 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-hpv-self-collection-for-cervical-cancer-screening-expanding-access-to-early-detection 2024-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-announces-global-offering-to-fund-microbiome-ecosystem-therapies-development 2024-05-14T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-to-present-promising-rvu120-and-synthetic-lethality-data-at-major-oncology-conferences 2024-05-14T15:39:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ind-application-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-05-14T13:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-advances-tumor-activated-immunotherapy-pipeline-with-phase-2-trial-of-xtx101-set-for-q3-2024 2024-05-14T11:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-announces-extension-of-u-s-food-and-drug-administration-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism 2024-05-14T01:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-s-genio-system-shows-strong-results-in-dream-pivotal-study-for-obstructive-sleep-apnea-treatment 2024-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-ceo-discusses-nv-387-s-broad-spectrum 2024-05-13T15:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-snb-101-for-small-cell-lung-cancer-treatment 2024-05-13T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-the-results-of-wegovys-longest-clinical-trial-yet-show-about-weight-loss-side-effects-and-heart-protection-cnn 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/plant-virus-nanoparticles-show-broad-protection-against-metastatic-cancers-in-preclinical-studies 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-reports-first-quarter-2024-financial-results-and-corporate-update 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-announces-date-for-envision-data-new-long-term-jelmyto-durability-data-and-reports-2024-first-quarter-financial-results-and-business-highlights 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-clinical-trial-to-treat-depression-in-oxford-university-study 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keyvibe-010-trial-evaluating-an 2024-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kite-and-arcellx-prepare-to-launch-phase-iii-multiple-myeloma-trial 2024-05-12T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/agenus-agen-q1-2024-earnings-call-transcript 2024-05-12T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/surprise-eli-lilly-is-racing-toward-yet-another-blockbuster 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-inc-kymr-q1-2024-earnings-call-transcript-highlights 2024-05-12T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-dermatitis-focused-rapt-therapeutics-stock-on-thursday 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/rapt-therapeutics-inc-reports-q1-2024-earnings-a-detailed-financial-overview 2024-05-12T13:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/fibrogen-inc-nasdaq-fgen-q1-2024-earnings-call-transcript 2024-05-12T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-incorporated-nasdaq-vrtx-q1-2024-earnings-call 2024-05-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/q1-2024-axsome-therapeutics-inc-earnings-call 2024-05-12T12:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study 2024-05-12T12:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-provides-business-updates-and-reports-first 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dll3-guided-therapies-show-promise-in-small-cell-lung-cancer-treatment 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-piwei-peiyuan-prescription-in-treating-chronic-atrophic-gastritis 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmather-receives-fda-goal-date-of-october-29-2024-for-priority-ketamine-anda-approval 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/reflections-on-the-new-fda-clinical-pharmacology-guidance-for-antibody-drug-conjugates 2024-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-reports-first-quarter-2024-financial-results-and-operational-progress 2024-05-09T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-provides-business-update-and-highlights-key-upcoming-milestones 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/r3-vascular-secures-87-million-in-series-b-financing-and-appoints-new-ceo 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/know-labs-to-present-clinical-research-at-the-2024-american-association-of-clinical-endocrinology-annual-meeting 2024-05-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-partners-with-catalent-to-advance-aav-immuno-gene-therapies-for-cancer 2024-05-08T15:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-receives-fda-approval-for-confirmatory-study-of-multikine-in-head-and-neck-cancer-treatment 2024-05-08T13:16:06+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-health-s-non-invasive-vagus-nerve-stimulation-shows-promising-results-in-clinical-trial 2024-05-08T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-medincell-announce-positive-phase-3-efficacy-results-for-tev-749-in-schizophrenia-treatment 2024-05-08T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-therapeutics-announces-first-quarter-2024-financial-update-and 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-in-class-hiv-1-treatment 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/participants-of-pioneering-crispr-gene-editing-trial-see-vision 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-a-fib-history-cleared-by-fda-for-use-in-clinical-trials 2024-05-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-acquires-mariana-oncology-for-1-billion-to-strengthen-radioligand-therapy-pipeline 2024-05-07T10:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/d3s-001-shows-superior-kras-g12c-inhibition-with-rapid-target-engagement-and-promising-clinical-activity 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denali-therapeutics-reports-first-quarter-2024-financial 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-first-quarter-2024-financial-results 2024-05-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-secures-final-china-patent-for-synthetic-anti-infectives-completing-global-protection-until-2035 2024-05-06T23:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-colosense-first-rna-based-noninvasive-colorectal-cancer-screening-test 2024-05-06T14:50:45+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-inc-advances-psychedelic-treatments-for-mental-health 2024-05-06T13:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/lyra-therapeutics-phase-3-enlighten-1-trial-for-chronic-rhinosinusitis-treatment-fails-to-meet-primary-endpoint 2024-05-06T11:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/mediar-therapeutics-advances-fibrosis-treatment-with-phase-1-trial-of-mtx-463 2024-05-06T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/idt-australia-secures-victorian-government-grant-to-establish-nation-s-first-commercial-adc-manufacturing-facility 2024-05-06T02:48:51+00:00 weekly 0.7 https://trial.medpath.com/news/systematic-review-of-phase-ii-and-iii-clinical-trials-for-relapsing-multiple-sclerosis 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/off-the-shelf-allogeneic-car-t-therapies-show-promise-for-b-cell-malignancies 2024-05-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-announces-results-from-atlas-showing-robust-ugn-102-durability-of-response-in-new-and-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-at-aua-2024 2024-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-launches-first-actemra-r-biosimilar-in-u-s-market-as-biosimilar-landscape-expands 2024-05-03T16:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-approves-oxbryta-for-sickle-cell-disease-following-price-reduction-agreement 2024-05-03T01:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/lifileucel-first-cellular-therapy-approved-for-cancer 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-reports-first-quarter-2024-financial-results-and-business-updates 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdas-accelerated-approval-of-sarepta-dmd-gene-therapy-comes-under-fire-biospace 2024-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ich-e6-r3-guidelines-set-to-transform-clinical-trial-quality-management-in-2025 2024-05-02T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-triple-combination-therapy-shows-promising-results-in-soft-tissue-sarcoma-phase-ii-trial 2024-05-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-reports-promising-results-for-xlrs-gene-therapy-using-novel-spreading-capsid 2024-05-01T14:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-new-draft-guidance-on-allogeneic-cell-based-medical-products 2024-05-01T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-explores-dual-listing-on-senior-exchange-following-successful-clinical-trials 2024-05-01T09:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/newron-s-evenamide-shows-breakthrough-results-in-treatment-resistant-schizophrenia-phase-ii-iii-trials 2024-05-01T02:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-announced-its-kras-g12c-inhibitor-reached-the-primary 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-florida-mrna-vaccine-shows-rapid-immune-response-against-glioblastoma-in-first-human-trial 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year 2024-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-secures-3-6-million-nih-grant-for-heart-failure-device-study 2024-04-30T12:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-04-30T02:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/the-u-s-food-drug-administration-fda-approves-updated-lupkynis-r-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program 2024-04-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-implements-historic-regulation-of-laboratory-developed-tests-with-new-final-rule 2024-04-29T09:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-resubmits-new-drug-application-to-u-s-food-and-drug-administration-for-oral-sulopenem 2024-04-29T02:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-awarded-european-union-orphan-drug-designation-for-nxc-201-in-multiple-myeloma-marketscreener 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-boston-biotechs-drug-for-ultra-rare-disease-of-immune-system-the-boston-globe 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-hercessitm-trastuzumab-strf-a-biosimilar-to-herceptin-r-trastuzumab-for-the-treatment-of-several-forms-of-her2-overexpressing-cancer 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-intensifies-scrutiny-of-orange-book-patent-listings-in-pharmaceutical-industry 2024-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launches-beqvez-gene-therapy-for-hemophilia-b-with-novel-warranty-program-at-3-5m 2024-04-28T22:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/india-s-cdsco-rejects-pfizer-s-clinical-trial-waiver-for-multiple-myeloma-drug-elranatamab 2024-04-27T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pfizer-s-3-5-million-gene-therapy-beqvez-for-hemophilia-b-treatment 2024-04-26T11:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/duchenne-muscular-dystrophy-gene-therapy-trial-shows 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv 2024-04-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-personalized-mrna-vaccine-for-melanoma-enters-uk-clinical-trials 2024-04-25T23:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/tease-3-study-reports-positive-interim-data-for-stargardt-disease-treatment 2024-04-25T16:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/starton-therapeutics-completes-enrollment-for-star-lld-phase-1b-trial-in-multiple-myeloma-reports-superior-safety-profile 2024-04-25T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/xaira-therapeutics-launches-with-record-1-billion-funding-to-revolutionize-ai-driven-drug-discovery 2024-04-25T00:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/car-nk-cell-therapy-shows-promise-as-safer-alternative-to-car-t-with-comparable-efficacy-in-early-clinical-trials 2024-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-cancer-treatment-the-promise-of-oncolytic-virotherapy-combinations 2024-04-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-announces-positive-preliminary-topline-results-from-tacti-003-cohort-b 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mirvetuximab-soravtansine-gynx-approved-for-ovarian-cancer 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-new-approval-for-wegovy-opens-medicare-coverage-for-millions-with-obesity 2024-04-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-immunitybio-s-anktiva-for-bladder-cancer-marking-major-milestone-for-soon-shiong-s-immunotherapy-approach 2024-04-23T20:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-promise-as-first-pharmaceutical-treatment-for-obstructive-sleep-apnea-in-obesity 2024-04-23T17:13:02+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-approved-in-europe-for-non-small-cell-lung-cancer-treatment 2024-04-23T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-xanamia-acw0009-phase-2b-trial-for-mci-and-mild-alzheimer-s-disease 2024-04-23T03:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-rilzabrutinib-luna-3-phase-3-study-met 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-partners-with-msd-to-test-novel-bispecific-antibody-bh3120-in-combination-with-keytruda 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-alvotech-teva-s-ustekinumab-biosimilar-for-psoriasis-and-psoriatic-arthritis 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-immunitybio-s-bladder-cancer-treatment-los-angeles-times 2024-04-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-pfizer-s-emblaveo-first-in-class-antibiotic-for-multi-drug-resistant-infections 2024-04-22T23:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/acadia-s-rett-syndrome-drug-under-priority-review-in-canada 2024-04-22T13:15:22+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2024-04-22T04:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-treats-first-lupus-patient-with-off-the-shelf-car-t-cell-therapy-ft819 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-allows-for-treatment-free-period-in-early-r-r-multiple 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-cheap-drug-may-slow-down-aging-a-study-will-determine-if-it-works-npr 2024-04-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-ind-for-arbor-biotechnologies-abo-101-gene-editing 2024-04-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tool-predicts-responses-to-cancer-therapy-using-single-cell-omics 2024-04-18T19:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-pembrolizumab-shows-improved-overall-survival-in-keynote-564-trial-for-ccrcc 2024-04-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-announces-rights-issue-to-raise-approximately-sek-60-million 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-an-immix-biopharma-subsidiary-on-track-to-dose-nxc-201-patients-in-united-states-biospace 2024-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-phase-iib-clinical-trial-listing-on-the-australian-new-zealand-clinical-trials-registry-anzctr 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ryzumvi-for-treating-drug-induced-mydriasis 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-ab-new-publication-highlights-safety-and 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-announces-latest-results-from-axess-trials-to-be-presented-at 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-announces-phase-2-clinical-trial-update-first-patient-completes-dosing-with-personalized-cancer-vaccine-evx-01 2024-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-sets-sights-on-launching-25-new-treatments-by-2030 2024-04-16T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/two-major-breakthroughs-in-fragile-x-syndrome-treatments 2024-04-16T13:33:24+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-presents-positive-18-month-phase-ib-trial-results-for-ab-1005-gene-therapy-in-parkinsons-disease 2024-04-16T12:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-advances-in-endometrial-cancer-focus-shifts-to-pmmr-disease-following-success-in-dmmr-population 2024-04-16T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/volastra-therapeutics-initiates-phase-ib-trial-of-sovilnesib-for-platinum-resistant-ovarian-cancer 2024-04-16T11:00:25+00:00 weekly 0.7 https://trial.medpath.com/news/cancervax-announces-promising-new-drug-to-treat-a-deadly-children-s-cancer 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spatial-comparison-of-molecular-features-associated-with 2024-04-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-announces-advancement-of-sanofi-developed-nk-cell-engager-sar443579-iph6101-to-phase-2-for-blood-cancer-patients 2024-04-15T13:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/11-clinical-trials-that-have-researchers-excited-in-2024 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/norgine-b-v-submits-marketing-authorisation-application-via-project 2024-04-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase 2024-04-12T22:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-viatris-vtrs-down-3-5-since-last-earnings-report 2024-04-12T13:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why 2024-04-12T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-rsv-shot-meets-goals-in-trial-of-high-risk-adults-under-age-60 2024-04-12T12:49:50+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug 2024-04-12T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/can-amivantamab-and-lazertinib-replace-osimertinib-in 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-odac-recognizes-mrd-as-an-accepted-end-point 2024-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-breakthrough-device-designation-for-ptau217-blood-test-to-aid-in-early-alzheimers-diagnosis 2024-04-11T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/vigeneron-doses-first-patient-in-phase-1b-clinical-trial-of-vg901-for-retinitis-pigmentosa-treatment 2024-04-11T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-parliament-approves-major-pharmaceutical-reform-package-with-modified-exclusivity-terms 2024-04-11T00:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimers-trial-brings-at-risk-patients-hope-for-the-future-but-new-doubts-in-the-present-the-globe-and-mail 2024-04-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-hope-for-men-with-metastatic-prostate-cancer 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/torl-biotherapeutics-announces-158-million-oversubscribed-series-b-2-financing-to-advance-the-clinical-development-of-its-novel-antibody-drug-conjugate-adc-oncology-pipeline 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update-the-globe-and-mail 2024-04-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aacr-2024-linvoseltamab-demonstrates-promising-results-in-heavily-pre-treated-multiple-myeloma-patients 2024-04-09T16:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-can-help-reduce-heart-failure-symptoms-even-when-people-don-t-lose-as-much-weight 2024-04-09T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/genomics-market-set-to-reach-157-47-billion-by-2033-driven-by-personalized-medicine-and-government-funding 2024-04-09T05:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-analysis-of-dna-fragmentomes-and-protein-biomarkers-noninvasively-detects-ovarian-cancer-news-releases-aacr 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-cort-completes-enrollment-in-ovarian-cancer-study 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-efficacy-of-tace-combined-with-tkis-and-icis-in-treating-hcc 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-immunotherapy-strategies-show-promise-in-overcoming-nsclc-treatment-resistance 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/augustine-therapeutics-raises-eur78-million-series-a-to-advance-novel-hdac6-inhibitor-for-charcot-marie-tooth-disease 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-could-reach-beyond-cancer-medicine-net 2024-04-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/supernus-provides-regulatory-update-for-spn-830 2024-04-08T22:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/oric-pharmaceuticals-unveils-promising-cancer-drug-data-at-aacr-meeting 2024-04-08T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-immunotherapy-market-set-to-reach-usd-296-billion-by-2033-growing-at-8-9-cagr 2024-04-08T11:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2024-04-08T04:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/uc-davis-health-pioneers-novel-heart-valve-repair-with-newly-approved-device 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-shorlas-oral-liquid-leukaemia-drug-nda-pharmaceutical-technology 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-parp-inhibitor-shows-promise-in-treating-hrr-deficient-breast-cancer 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-s-ocu400-becomes-first-gene-therapy-to-enter-phase-3-for-broad-retinitis-pigmentosa-treatment 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-fda-filing-acceptance-of-new-drug 2024-04-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-most-cancer-drugs-with-accelerated-fda-approval-fail-to-demonstrate-clinical-benefit-after-five-years 2024-04-07T18:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-mrna-vaccine-shows-promise-in-fighting-pancreatic-cancer 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/single-injection-of-zilebesiran-reduces-blood-pressure-by-up-to-12-mmhg-in-phase-2-trial 2024-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-announces-successful-completion-of-phase-3-clinical-trial-for-alzheimers-disease-agitation 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-secures-key-patent-for-modular-robotic-system-expanding-market-potential-to-6-million-procedures 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clene-advances-cnm-au8-toward-potential-als-approval-with-fda-meetings-and-biomarker-analysis 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-use-of-trikafta-for-cystic-fibrosis-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-for-verastem-oncology-s-new-drug-application-for-recurrent-kras-mutant-lgsoc-treatment 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-expands-calma-phase-2-trial-for-alzheimer-s-agitation-treatment-with-new-oklahoma-site 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/signatera-mrd-test-shows-exceptional-survival-outcomes-in-muscle-invasive-bladder-cancer-surveillance 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aspire-biopharma-s-sublingual-aspirin-shows-twice-faster-action-in-heart-attack-treatment-trial 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-r-is-the-first-and-only-bcma-targeted 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/odronextamab-demonstrates-high-efficacy-in-lymphoma-treatments-at-ash-meeting 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-and-biogen-initiate-phase-3-emperor-trial-for-zorevunersen-in-dravet-syndrome 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-ptc-therapeutics-nda-for-sepiapterin-to-treat-pku 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-aficamten-shows-superior-cardiac-benefits-over-standard-treatment-in-hypertrophic-cardiomyopathy 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-announces-alignment-with-global-regulatory-agencies 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-confirms-superior-efficacy-of-perioperative-immunotherapy-plus-chemotherapy-in-resectable-nsclc 2024-04-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-phase-3-trial-of-mk-1084-plus-pembrolizumab-for-kras-g12c-mutated-nsclc 2024-04-04T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-real-world-evidence-revolution-new-paradigm-for-biotech-companies 2024-04-04T06:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/india-launches-world-s-most-affordable-car-t-cell-therapy-at-one-tenth-international-cost 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-expands-clinical-development-of-cb-010-with-fda-clearance-of-ind-in-lupus 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tpvr-with-self-expanding-harmony-valve-associated-with 2024-04-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-requires-fast-track-designation-for-subcutaneous-formulation-of-leqembi-for-alzheimer-s-disease 2024-04-03T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/court-rules-in-favor-of-arbutus-in-patent-dispute-over-moderna-s-covid-19-vaccine-delivery-technology 2024-04-03T19:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/ind-application-submitted-to-fda-for-synkir-310-trial-in-relapsed-refractory-b-nhl 2024-04-03T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-strategic-decisions-shaping-the-future-of-cell-and-gene-therapy-development 2024-04-03T04:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/behavioral-science-emerges-as-key-strategy-for-driving-adoption-of-novel-therapies-in-biopharma 2024-04-03T01:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-fda-approval-for-first-denosumab-biosimilars-in-us-and-canada 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-of-adjuvant-cemiplimab-versus-placebo-after-surgery-for-high-risk-cutaneous-squamous-cell-carcinoma 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-hits-reset-on-drug-from-2-5b-deal-after-lower-than-projected-efficacy-in-trials 2024-04-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-completes-zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic-biliary-tract-cancer 2024-04-02T18:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-preference-for-bladder-sparing-treatments-in-high-risk-nmibc-patients 2024-04-02T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2024-04-02T01:04:35+00:00 weekly 0.7 https://trial.medpath.com/news/direct-and-selective-pharmacological-disruption-of-the-yap 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eflornithine-for-neuroblastoma-ema-approval-timelines-and-how-to-avoid 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/agios-strategy-shift-pays-off-with-fda-approval-of-first-drug-for-rare 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pharmaessentia-interferon-drug-for-a-rare-type-of-blood 2024-04-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cretostimogene-monotherapy-demonstrated-75-2-complete-response-rate-in 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-denali-neuro-drug-fails-mid-stage-trial-in-als-ms-study-is 2024-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-mfars-in-pediatric-friedreich-s-ataxia-insights-from-the-fachild-study 2024-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-sequel-s-twiist-aid-system-first-insulin-pump-to-directly-measure-every-micro-dose 2024-03-30T19:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-flexes-its-new-accelerated-approval-authorities-hoping-to 2024-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-pharmaceuticals-announces-resubmission-of-new-drug-application-for-etripamil-for-treatment-in-paroxysmal-supraventricular-tachycardia 2024-03-28T19:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-announces-clinical-development-plan-for-resubmission-of-new-drug-application-for-reproxalap-in-dry-eye-disease 2024-03-28T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-national-medical-products-administration-accepts 2024-03-28T14:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-shows-consistent-benefit-in-resectable-nsclc-regardless-of-neoadjuvant-treatment-duration 2024-03-28T14:05:51+00:00 weekly 0.7 https://trial.medpath.com/news/vicore-s-buloxibutid-shows-promising-lung-function-improvement-in-phase-2a-ipf-trial 2024-03-28T10:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-fda-update-on-pdufa-target-action-date-for-govorestat-for-the-treatment-of-classic-galactosemia 2024-03-28T00:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/u-k-becomes-the-first-country-to-release-detailed-data-on-sponsors-that-fail-to-register-clinical-trials 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-2023-full-year-results-and-2024-outlook 2024-03-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-joint-ventures-from-2016-2024 2024-03-27T20:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-s-obesity-drug-shows-promising-results-in-reducing-fat-with-minimal-muscle-loss 2024-03-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-warns-against-high-concentration-lidocaine-products-in-cosmetic-procedures 2024-03-27T10:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-stok-up-on-upbeat-dravet-syndrome-study-data 2024-03-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsed-refractory-kmt2ar-acute-leukemia 2024-03-26T02:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/intrabio-announces-u-s-fda-accepts-new-drug-application-for-ib1001-for-the-treatment-of-niemann-pick-disease-type-c 2024-03-26T02:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/avecho-launches-largest-phase-iii-trial-of-cbd-for-insomnia-in-australia 2024-03-26T00:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-s-vabysmo-receives-japanese-approval-for-retinal-vein-occlusion-treatment 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-shows-belumosudil-s-efficacy-in-treating-chronic-graft-versus-host-disease 2024-03-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-survivor-funds-clinical-trial-to-aid-future-patients 2024-03-25T17:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-completes-dosing-in-pivotal-study-for-oral-postpartum-depression-treatment-lpcn-1154 2024-03-25T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-complete-response-letters-for-regeneron-s-odronextamab-in-non-hodgkin-lymphoma 2024-03-25T07:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-secures-global-patent-protection-for-cm-101-antibody-targeting-primary-sclerosing-cholangitis 2024-03-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceutical-industry-leadership-shuffle-major-executive-appointments-signal-strategic-shifts-across-biotech-and-pharma 2024-03-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-review-of-the-clinical-efficacy-of-fda-approved-antibody 2024-03-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pan-foundation-study-reveals-c-grade-for-u-s-healthcare-access-highlighting-systemic-disparities 2024-03-22T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-advances-ruvembri-to-phase-3-trial-for-sarcopenia-treatment-following-promising-phase-2-results 2024-03-22T07:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-therapeutics-advances-phase-3-trial-for-novel-once-weekly-acne-treatment-dmt310 2024-03-21T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-patent-office-upholds-umeclidinium-vilanterol-combination-patent-despite-opposition-challenges 2024-03-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-drug-discovery-industry-leaders-share-latest-advances-at-london-conference 2024-03-21T07:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-support-services-market-set-to-reach-47-1-billion-by-2032-amid-growing-outsourcing-trend 2024-03-21T05:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/elixir-medical-receives-fda-breakthrough-device-designation-for-the-dynamx-btk-system-for-use-in-the-treatment-of-chronic-limb-threatening-ischemia-resulting-from-below-the-knee-arterial-disease 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scandion-oncology-reports-promising-updated-phase-ii-corist-data 2024-03-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-updates-on-clinical-trials-and-financials-for-2023 2024-03-20T12:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-combo-misses-survival-endpoints-in-endometrial-cancer-trial 2024-03-20T11:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-reports-promising-early-stage-data-for-thyroid-eye-disease-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-dfd-29-for-rosacea-treatment 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stat-readout-orchard-acelyrin-novo-astrazeneca 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-announces-positive-phase-1-2-poc-data-for-first-subcutaneous-anti-igf-1r-to-demonstrate-clinical-responses-in-thyroid-eye-disease 2024-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-study-on-friedreich-s-ataxia-aims-to-enhance-understanding-and-treatment 2024-03-19T19:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-amycretin-pill-shows-promising-13-weight-loss-in-early-trial 2024-03-19T15:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-plans-to-resubmit 2024-03-19T14:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-prepares-to-seek-approval-for-menopause-drug-elinzanetant-following-positive-phase-3-trial-results 2024-03-19T11:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/nvidia-expands-ai-healthcare-footprint-with-major-drug-discovery-partnerships 2024-03-19T07:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/petros-pharmaceuticals-successfully-launches-ai-tool-in 2024-03-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-non-opioid-pain-medications-hold-promise-but-face-challenges 2024-03-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocuterra-s-phase-ii-diabetic-retinopathy-trial-fails-to-meet-endpoints 2024-03-15T09:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-early-referral-system-to-expand-car-t-cell-access-in-large-b-cell-lymphoma 2024-03-15T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-publishes-data-for-its-first-in-class-mkk4 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expired-rfa-da-25-052-tools-for-decentralized-clinical-trials 2024-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/protein-discovery-offers-new-hope-for-treating-aggressive-cancer 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-drug-trial-for-rare-chronic-kidney-disease-achieves-key 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mda-2024-dmd-cell-therapy-cap-1002-continues-to-preserve-limb 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilgamesh-pharmaceuticals-awarded-14-million-national-institute-on-drug-abuse-grant-to-advance-novel-cardiac-safe-ibogaine-analog-for-the-treatment-of-opioid-use-disorder 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/korean-drugmakers-lead-in-biosimilar-market-and-new-denosumab-eculizumab-deals 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffratm-resmetirom-for-the-treatment-of-patients-with-noncirrhotic-nonalcoholic-steatohepatitis-nash-with-moderate-to-advanced-liver-fibrosis 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-full-year-2023-financial-results-and 2024-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lyt-200-receives-fda-orphan-drug-designation-for-acute-myeloid-leukemia-treatment 2024-03-13T18:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-zacks-analyst-blog-highlights-moderna-rapt-therapeutics-iovance-sarepta 2024-03-13T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-clinical-trials-a-2024-update 2024-03-13T17:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/q4-2023-clearside-biomedical-inc-earnings-call 2024-03-13T13:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-inc-tyra-reports-increased-r-d-investments-amid-pipeline 2024-03-13T13:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-pmvp-reports-full-year-2023-financial-results 2024-03-13T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-se-bntx-q4-2023-earnings-call-transcript 2024-03-13T11:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/q4-2023-vaxart-inc-earnings-call 2024-03-13T11:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/digital-evolution-in-clinical-trials-epros-show-97-compliance-rate-in-latest-study 2024-03-13T09:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-clinical-trial-results-show-dramatic-regression-of-glioblastoma-after-next-generation-car-t-therapy 2024-03-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-announces-promising-preclinical-findings-for-glp-1-gene-therapy-in-diabetes-and-obesity 2024-03-12T11:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/biovica-signs-master-service-agreement-to-support-next-generation-cdk4-6-inhibitor-development-for-breast-cancer 2024-03-12T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-fda-breakthrough-therapy 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-combines-cisplatin-pembrolizumab-and-radiation-therapy-for-advanced-vulvar-squamous-cell-carcinoma 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-comprehensive-clinical-trials-to-address-debilitating-long-covid-symptoms 2024-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-b-corp-acquires-cannabis-patents-valued-at-122-million-through-court-assignment 2024-03-11T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/nusano-opens-radiochemistry-laboratory-to-advance-medical-radioisotope-production-for-cancer-therapy 2024-03-11T03:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-and-pembrolizumab-show-significant-survival-benefit-in-urothelial-cancer-treatment 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-and-merck-report-promising-phase-2-results-for-once-weekly-hiv-combination-therapy 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-top-line-results-from-its-globenewswire 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denver-lab-developing-first-of-its-kind-tool-for-early-ovarian-cancer-detection-cbs-colorado 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients-march-11-2024-at-08-02-am-edt-marketscreener 2024-03-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-obtains-fda-approval-for-ai-discovered-cancer 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/benefit-of-belantamab-mafodotin-based-regimen-supported-in-multiple 2024-03-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-nivolumab-offers-a-promising-alternative-for-kidney-cancer-treatment 2024-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promontory-therapeutics-completes-enrollment-in-phase-2-trial-of-pt-112-for-late-stage-metastatic-prostate-cancer 2024-03-08T08:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-convene-advisory-committee-for-eli-lilly-s-alzheimer-s-drug-donanemab 2024-03-08T07:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/sexually-transmitted-infections-in-san-francisco-have 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/als-drug-fails-large-clinical-trial-and-may-be-withdrawn-from-market-cnn 2024-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuron-announces-positive-results-for-travelan-r-progressing-to-phase-3-clinical-trials-in-the-us 2024-03-07T11:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-adjuvant-vs-neoadjuvant-only-pd-1-and-pd-l1-inhibitors-for 2024-03-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-plus-nivolumab-emerges-as-preferred-first-line-treatment-for-advanced-renal-cell-carcinoma 2024-03-06T22:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-for-phospho-tau-217-blood-test-for-alzheimer-s-disease 2024-03-06T19:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/bluerock-therapeutics-reports-positive-18-month-data-in-phase-i-trial-for-parkinson-s-disease-treatment 2024-03-06T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-initiates-phase-iii-trial-of-cadonilimab-bispecific-antibody-for-pd-l1-negative-nsclc 2024-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-cgb-500-for-atopic-dermatitis-treatment 2024-03-05T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-teclistamab-data-shows-comparable-efficacy-to-clinical-trials-despite-higher-toxicity-rates-in-multiple-myeloma 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiztm-for 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment 2024-03-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/transformative-trends-reshape-pharmaceutical-r-d-landscape-in-2024-ai-crispr-and-rare-disease-innovation-take-center-stage 2024-03-04T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-design-in-precision-medicine 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-trigeminal-neuralgia-clinical-trials-for-2024-san-francisco 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rop-et-a-prospective-phase-iii-trial-investigating-the 2024-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-phase-3-trial-tests-efzofitimod-as-steroid-sparing-treatment-for-sarcoidosis 2024-03-01T07:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trials-directive-transition-deadline-looms-companies-must-act-by-january-2025 2024-03-01T01:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-files-marketing-authorisation-application-with-ema-for-resminostat 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-receives-ind-approval-for-p53-y220c-activator-jab-30355-in-the-us 2024-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/niaid-halts-clemastine-arm-of-ms-trial-after-fivefold-increase-in-disease-progression 2024-02-29T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-reveals-significant-disparities-in-psoriasis-impact-across-racial-and-ethnic-groups 2024-02-29T11:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/cu-cancer-center-researchers-advance-novel-cancer-therapy-with-svc112-molecule 2024-02-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fire1-completes-enrollment-in-u-s-early-feasibility-study-of 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-lifileucel-for-unresectable-or-metastatic-melanoma 2024-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/til-therapy-offers-new-hope-for-patients-with-metastatic-melanoma 2024-02-27T15:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-phase-iii-clinical-trial-to-europe 2024-02-27T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-reduces-allergic-reactions-to-multiple-foods-in-nih-clinical-trial 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/memorial-sloan-kettering-cancer-center-now-enrolling-patients-in-phase-1-2-clinical-trial-of-imunons-imnn-001-in-combination-with-bevacizumab-in-advanced-ovarian-cancer 2024-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pcm-trials-acquires-emvenio-research-to-expand-decentralized-clinical-trial-access-for-underrepresented-communities 2024-02-26T10:40:40+00:00 weekly 0.7 https://trial.medpath.com/news/global-rare-disease-crisis-3-5-million-uk-patients-face-critical-healthcare-challenges 2024-02-26T01:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-analysis-reveals-decade-of-growth-in-rare-pediatric-disease-drug-development-through-priority-review-voucher-program 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/thervacb-therapeutic-vaccine-begins-first-in-human-trial-for-chronic-hepatitis-b 2024-02-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-shows-promise-for-chronic-gvhd-as-real-world-data-confirms-ruxolitinib-s-sustained-activity 2024-02-24T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intrommune-therapeutics-presents-supporting-data-introducing-a 2024-02-23T23:22:33+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-key-trends-and-challenges-in-rare-disease-drug-development-for-2024 2024-02-23T07:24:50+00:00 weekly 0.7